Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
Authors:
Open Access
- 24 January 2024
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (1) , 1-14
Abstract
Ritlecitinib, an orally available Janus kinase 3 and tyrosine kinase inhibitor being developed for the treatment of alopecia areata (AA), is highly soluble across the physiological pH range at the therapeutic dose. As such, it is expected to dissolve rapidly in any in vitro dissolution conditions. However, in vitro dissolution data showed slower dissolution for 100-mg capsules, used for the clinical bioequivalence (BE) study, compared with proposed commercial 50-mg capsules. Hence, a biowaiver for the lower 50-mg strength using comparable multimedia dissolution based on the f2 similarity factor was not possible. The in vivo relevance of this observed in vitro dissolution profile was evaluated with a physiologically based pharmacokinetic (PBPK) model. This report describes the development, verification, and application of the ritlecitinib PBPK model to translate observed in vitro dissolution data to an in vivo PK profile for ritlecitinib capsule formulations. Virtual BE (VBE) trials were conducted using the Simcyp VBE module, including the model-predicted within-subject variability or intra-subject coefficient of variation (ICV). The results showed the predicted ICV was predicted to be smaller than observed clinical ICV, resulting in a more optimistic BE risk assessment. Additional VBE assessment was conducted by incorporating clinically observed ICV. The VBE trial results including clinically observed ICV demonstrated that proposed commercial 50-mg capsules vs clinical 100-mg capsules were bioequivalent, with > 90% probability of success. This study demonstrates a PBPK model–based biowaiver for a clinical BE study while introducing a novel method to integrate clinically observed ICV into VBE trials with PBPK models. Trial registration: NCT02309827, NCT02684760, NCT04004663, NCT04390776, NCT05040295, NCT05128058. Graphical AbstractKeywords
This publication has 25 references indexed in Scilit:
- Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and SimulationCPT: Pharmacometrics & Systems Pharmacology, 2019
- Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia AreataJAMA Dermatology, 2019
- Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their familiesJournal of the American Academy of Dermatology, 2018
- Alopecia areataNature Reviews Disease Primers, 2017
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansJournal of Medicinal Chemistry, 2017
- Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance MechanismsDrug Metabolism and Disposition, 2017
- Epidemiology and burden of alopecia areata: a systematic reviewClinical, Cosmetic and Investigational Dermatology, 2015
- The autoimmune basis of alopecia areata: A comprehensive reviewAutoimmunity Reviews, 2015
- Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies.1994
- Lifetime prevalence of psychiatric disorders in patients with alopecia areataComprehensive Psychiatry, 1991